Clinical Trial: Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168317) titled 'Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL' on Sept. 04.

Brief Summary: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: New Diagnosed Angioimmunoblastic T-Cell Lymphoma

Intervention: DRUG: tislelizumab in combination with cyc...